MX2024006933A - Formas en estado solido de un inhibidor de fgfr. - Google Patents
Formas en estado solido de un inhibidor de fgfr.Info
- Publication number
- MX2024006933A MX2024006933A MX2024006933A MX2024006933A MX2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A MX 2024006933 A MX2024006933 A MX 2024006933A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- state forms
- fgfr inhibitor
- forms
- yclopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287212P | 2021-12-08 | 2021-12-08 | |
| PCT/US2022/081060 WO2023107980A1 (en) | 2021-12-08 | 2022-12-07 | Solid state forms of an fgfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024006933A true MX2024006933A (es) | 2024-08-26 |
Family
ID=86731361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024006933A MX2024006933A (es) | 2021-12-08 | 2022-12-07 | Formas en estado solido de un inhibidor de fgfr. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250059170A1 (https=) |
| EP (1) | EP4444302A4 (https=) |
| JP (1) | JP2024542840A (https=) |
| KR (1) | KR20240119095A (https=) |
| CN (1) | CN118804748A (https=) |
| AU (1) | AU2022407440A1 (https=) |
| CA (1) | CA3239792A1 (https=) |
| CL (1) | CL2024001679A1 (https=) |
| IL (1) | IL313359A (https=) |
| MX (1) | MX2024006933A (https=) |
| TW (1) | TW202332432A (https=) |
| WO (1) | WO2023107980A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| AU2022407439A1 (en) * | 2021-12-08 | 2024-06-27 | Kinnate Biopharma Inc. | Treatment of cancer with an fgfr kinase inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10124003B2 (en) * | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| CN107840842A (zh) * | 2016-09-19 | 2018-03-27 | 北京天诚医药科技有限公司 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| EP3969442A4 (en) * | 2019-05-17 | 2023-08-02 | Kinnate Biopharma Inc. | FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS |
| US11345681B1 (en) * | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
-
2022
- 2022-12-07 KR KR1020247022100A patent/KR20240119095A/ko active Pending
- 2022-12-07 CA CA3239792A patent/CA3239792A1/en active Pending
- 2022-12-07 US US18/717,390 patent/US20250059170A1/en active Pending
- 2022-12-07 EP EP22905319.4A patent/EP4444302A4/en active Pending
- 2022-12-07 AU AU2022407440A patent/AU2022407440A1/en active Pending
- 2022-12-07 MX MX2024006933A patent/MX2024006933A/es unknown
- 2022-12-07 IL IL313359A patent/IL313359A/en unknown
- 2022-12-07 TW TW111147070A patent/TW202332432A/zh unknown
- 2022-12-07 CN CN202280091311.6A patent/CN118804748A/zh active Pending
- 2022-12-07 JP JP2024534140A patent/JP2024542840A/ja active Pending
- 2022-12-07 WO PCT/US2022/081060 patent/WO2023107980A1/en not_active Ceased
-
2024
- 2024-06-06 CL CL2024001679A patent/CL2024001679A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202332432A (zh) | 2023-08-16 |
| IL313359A (en) | 2024-08-01 |
| KR20240119095A (ko) | 2024-08-06 |
| EP4444302A1 (en) | 2024-10-16 |
| WO2023107980A1 (en) | 2023-06-15 |
| AU2022407440A1 (en) | 2024-06-20 |
| CA3239792A1 (en) | 2023-06-15 |
| CL2024001679A1 (es) | 2024-11-29 |
| US20250059170A1 (en) | 2025-02-20 |
| CN118804748A (zh) | 2024-10-18 |
| EP4444302A4 (en) | 2025-09-03 |
| JP2024542840A (ja) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500171A1 (en) | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor | |
| MX2024006933A (es) | Formas en estado solido de un inhibidor de fgfr. | |
| MX2009007337A (es) | Indazoles sustituidos con 5-piridinona. | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| MX2009009591A (es) | Aminopirimidinas utiles como inhibidores de proteinas cinasas. | |
| ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
| BRPI0615307A2 (pt) | agonistas de adrenorreceptor alfa2c | |
| CL2008001943A1 (es) | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
| NO20091326L (no) | Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| SI2049475T1 (sl) | Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1 | |
| NO20084435L (no) | C-MET proteinkinaseinhibitorer | |
| CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
| WO2007115289A3 (en) | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer | |
| EP2592073A3 (en) | Human protein tyrosine phosphatase inhibitors and their use | |
| GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
| NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
| SG171649A1 (en) | Dpp iv inhibitor formulations | |
| MY163477A (en) | Pyrimidinyl-pyridazinone derivatives | |
| WO2008002571A3 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| NO20090157L (no) | Tienpyrimidiner anvendelige som modulatorer av ionekanaler | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| ATE471311T1 (de) | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 | |
| TNSN08432A1 (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |